Female renal transplant recipients (RTRs) have an increased risk for developing human papillomavirus (HPV)-related (pre)malignant lesions of the genital tract. This study aims to assess the genital prevalence of HPV before and after renal transplantation (RT). In female patients who were counseled for RT at the Radboud University Medical Center Nijmegen, the Netherlands, gynecological examination was performed at first visit, and 1 and 2 years later. HPV self-sampling and questionnaires on sexual behavior were performed every 3 months. In 65 patients who underwent RT, the high-risk human papillomavirus (hrHPV) prevalence as assessed with the highly sensitive SPF 10 -LiPA 25 test increased significantly from 19% before to 31% after RT (p = 0.045). Based upon the clinically validated Cobas 4800 HPV test, the hrHPV prevalence increased from 10% before to 14% after RT (p = 0.31). During follow-up, no changes in sexual behavior were reported. Thirty-three patients who did not undergo RT showed a hrHPV prevalence of 21% at study entry and of 27% after 12 months with the sensitive test, and a stable prevalence of 16% with the clinically validated test. The results of this study indicate that activation of latent HPV infections may contribute to the increased risk of HPV-related (pre)malignant lesions in female RTRs.
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Introduction
Organ transplantation is the treatment of choice for patients with failing kidneys, heart, lungs, pancreas, or liver. To prevent rejection, organ transplant recipients have to use lifelong immunosuppressive therapy. This makes them more susceptible to the development of malignancies with standardized incidence ratios (SIRs) ranging from 2.1 to 4.0 (1-6).
It is well known that high-risk human papillomaviruses (hrHPVs) are causative in the development of genital premalignant or malignant lesions ((pre)malignancies), mainly due to HPV 16 and HPV 18. In fact, 95% of all cervical malignancies and about 20% of the vulvar malignancies are hrHPV-related (7) . We previously showed that using a highly sensitive detection assay, the point prevalence of genital HPV infections in women aged 18-29 in the Netherlands is 19%, with an HPV 16 and HPV 18 prevalence of 2.8% and 1.4%, respectively (8) . The majority of hrHPV infections in the general population will be cleared within 1 year. It is thought that only those women in whom the virus is persistently present over a longer period have an increased risk of genital (pre)malignancies.
HPV-positive anogenital tract (pre)malignancies (e.g. cervix, vulva, and anus) are found at a significantly higher rate in renal transplant recipients (RTRs) than in immunocompetent individuals with SIRs between 1.0 and 2.5 for cervical cancer and between 7.3 and 23.9 for vulva/vaginal cancer (1, 3, 5, 6, 9) , and belong to the most frequent (pre)-malignancies in RTRs (10) (11) (12) . In observational and other studies on posttransplant malignancies in female RTRs, 11% developed cervical cancer and 4% developed vulvar cancer (13) . Another study of our group showed that (pre)malignancies are primarily diagnosed early (within 3 years) or late (>10 years) after transplantation (14) .
Data on the prevalence of genital HPV infections in RTRs are scarce. One study showed a prevalence of HPV of 62.8% in 35 female RTRs (15) . In contrast with the general population in whom about 20% of the vulvar lesions are HPV positive, Brown et al found that all vulvar lesions in transplant patients were HPV positive (16) . Recently, Meeuwis et al (17) showed a cervicovaginal HPV prevalence of 27.1% in a large cohort of female RTRs after renal transplantation (RT).
The HPV prevalence in female RTRs has been mainly assessed after the transplantation. The natural course of hrHPV infections from the time before to the period after RT is unknown. Therefore, the aim of this study was to assess the prevalence of genital HPV in female RTRs before and after transplantation. More specifically, we were interested to investigate whether the use of immunosuppressive therapy has an effect on the prevalence of hrHPV. Knowledge with respect to the biological behavior of genital HPV infections might provide a scientific basis for rational means to prevent anogenital malignancies in the future, such as HPV vaccination and screening.
Patients and Methods

Study population and immunosuppressive treatment
Between February 28, 2012 and April 1, 2015, female patients with end-stage renal disease (ESRD), who had an appointment at the outpatient clinic of the Department of Nephrology at the Radboud University Medical Center (RadboudUMC) to judge whether they were appropriate candidates for RT were invited to participate in this study. See Figure 1 for inclusion and exclusion criteria. All patients underwent renal transplantation in the RadboudUMC. After transplantation, patients were treated with tacrolimus, mycophenolate mofetil, and prednisone as immunosuppressive therapy. From August 2014, induction therapy with basiliximab was added to the immunosuppressive therapy. Acute rejection episodes were treated with methylprednisolone followed by antithymocyte globulin in case of steroid-resistant rejection. This study was approved by the local medical ethics committee (protocol number: 2011/425).
Gynecological examination
Patients who returned the informed consent form were examined by the clinical researcher of the Department of Obstetrics & Gynecology. This first appointment with the researcher included detailed medical history, dermatological and gynecological examination with inspection of the external genitalia and perianal area, inspection of the vagina and cervix (vaginal vault in absence of the uterus), and collection of cytology by a smear of the cervix or the vaginal vault. This complete gynecological examination was repeated at 1 and 2 years after inclusion in the study.
Cytology
The Bethesda system 2001 was used for cytological classification. In case of normal cytology, no further tests or treatments were necessary. When the cytology showed atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL), the smear was repeated after 6 months according to hospital protocol. In case of high-grade squamous intraepithelial lesion (HSIL), a colposcopic examination was performed and patients were treated according to current guidelines.
Self-sampling
The patient was asked to self-collect a cervicovaginal sample with a collection device (a small brush packaged in an individual sterile cover, Rovers Evalyn Brush â ; Rovers Medical Devices B.V., Oss, the Netherlands [18] ) at the first visit and at home every 3 months during follow-up. Therefore, patients were sent an HPV self-sample kit every 3 months. This kit contained a collection device, detailed instructions on how to perform the cervicovaginal self-sampling (written and in cartoon), and a return package consisting of a leak-proof seal bag, absorption sheet, and an easy-slider plastic return envelope.
Specimen preparation and DNA extraction
The dry Evalyn Brush was resuspended in 1. 
HPV detection and genotyping
For the HPV detection on the collected self-sampling material, two HPV detection methods were used. The first is the highly analytical sensitive short-polymerase chain reaction-fragment assay (SPF 10 -LiPA 25 ; Labo BioMedical Products B.V., Rijswijk, the Netherlands). This assay has been widely used for epidemiological and vaccination studies, because of its very high analytical sensitivity (19) . This assay was included to identify the smallest foci of detectable HPV. However, because of its high analytical sensitivity, the SPF 10 -LiPA 25 assay has a very low clinical specificity (19) . As a second test, we therefore used the clinically validated Cobas 4800 HPV test (Roche), which enables detection of chronic productive infections that are potentially related to cervical abnormalities (20) . The data obtained with this test may guide future clinical management of transplant patients.
The SPF 10 -LiPA 25 assay amplifies a small fragment of 65-bp from the L1 open reading frame and allows detection of a broad range of HPV genotypes (21) (22) (23) . Next, HPV DNA enzyme immunoassay (DEIA) was used, which comprises a defined cocktail of digoxigenin-labeled probes to detect a broad spectrum of HPV mucosal genotypes. All HPV DNApositive samples were genotyped subsequently with a line probe assay (LiPA 25 ) by reverse hybridization with type-specific probes for mucosal HPV genotypes 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59 , 66, 68/73, 70, and 74 (22) . The LiPA strips were interpreted visually, using the standard reference guide. When samples tested positive using the DEIA, but showed no results on the LiPA strip, the SPF 10 amplimer was analyzed by direct sequence analysis with the BigDye Terminator cycle sequencing kit (Applied Biosystems, Nieuwerkerk a/d Ijssel, the Netherlands). The sequences were used as a query for screening in the GenBank database (www.ncbi.nlm.nih.gov) with BLAST software (24) . HPV genotypes were assigned when a complete match between the 22-bp interprimer region and an HPV sequence in GenBank was found.
Genotypes not available on the LiPA strip and without a complete match in GenBank were considered HPV genotype "X." Low-risk HPV (lrHPV) genotypes were defined as genotype 6, 11, 34, 40, 42, 43, 44, 54, (phrHPV) genotypes (25) . For analytical purposes, they were defined as hrHPV genotypes in this study. HPV genotypes 3, 12, 20, and 76 were identified by sequencing as cutaneous genotypes. These HPV genotypes were regarded as contamination during sample handling (self-sample) and were not taken into account in the calculation of HPV prevalence rates.
The self-sampling material of all included patients at first examination and of all the patients who underwent a RT, before and after transplantation, was also tested with the clinically validated Cobas 4800 HPV test (Roche) according to the manufacturer's recommendations in the laboratory of the Department of Medical Microbiology, RadboudUMC (20 
Questionnaires
Patients filled out questionnaires on relations/sexual behavior at the start of the study and at every 3-monthly self-sampling occasion, and they were specifically asked whether there were any changes in their relationship and/or sexual behaviors. The questionnaires are available as Supplemental material.
Statistical analysis
Data of all women who gave informed consent and underwent gynecological examination, including an HPV test, were included in the analyses. The prevalence of HPV infection after transplantation was only assessed in patients who underwent a transplantation within 3 years after inclusion in the study. In the primary analysis, we compared the HPV prevalence before (measurement closest to RT in 6-month period preceding RT) and after (latest measurement in the period between month 3 and month 12 after RT) transplantation in patients with both measurements available. In a secondary analysis, we used a scoring system to quantify the degree of HPV positivity in multiple measurements before and after RT; a score of 0 corresponded with 100% negative measurements and a score of 100 with 100% positive measurements. Patients who were included in the study, but did not undergo a RT during the follow-up period, were used as a control group. In these patients, HPV prevalence at first examination and the latest measurement in a 12-month period were used in the analysis.
A model based on the generalized estimating equations (GEE), with a binomial distribution and identity link, was used to analyze the pre-and posttransplant prevalence and the change in prevalence. The mean scores calculated from multiple measurements before were compared with the mean scores after RT by a paired samples t-test. Continuous variables were described by medians (and range) or means (and standard deviation). Discrete variables were described by frequencies and percentages. The genotype of each HPV infection was assessed and described per time point. The results from the questionnaires asking for sexual behavior were summarized according to the transplantation status of the patient. All data were anonymously stored in an electronic database. Statistical analysis was performed using IBM SPSS Statistics 20 (IBM Corp, Armonk, NY). Two-sided p-values <0.05 were regarded as statistically significant.
Results
During the study period, 351 patients were referred to the outpatient clinic of the RadboudUMC to judge whether they were appropriate candidates for RT. During the study period, 65 patients underwent a RT. The remaining 58 patients did not receive a kidney graft for various reasons; 15 patients were found unfit for transplantation and were excluded. See Figure 1 for an overview of the inclusions. In total, 13 patients (3 underwent RT) were lost to followup: 4 patients died (3 patients due to cardiac problems and 1 patient developed a brain tumor), 5 patients left the study because it was too time consuming or their physical condition was impaired, 3 patients did not respond to reminders, and 1 patient due to psychiatric problems. The general patient characteristics, details on their renal disease and treatment, and gynecological characteristics at first contact are summarized in Table 1 .
The median follow-up after transplantation (last follow-up date October 12, 2015) was 15 months (range 0-29 months). Five patients did not have any measurement after transplantation and one patient did not have any measurements before transplantation. Finally, HPV prevalence before and after transplantation was determined in 59 patients with both the clinically validated HPV test and the highly sensitive HPV test.
As assessed with the highly sensitive HPV test, the overall HPV prevalence increased from 25% (95% CI 14-37%) before transplantation to 39% (95% CI 27-51%) after transplantation using the definition of the primary outcome measure (p = 0.04; Table 2 ). The hrHPV prevalence increased from 19% (95% CI 9-29%) before transplantation to 31% (95% CI 19-42%) after transplantation (p = 0.045). The hrHPV prevalence before transplantation (median time to transplantation: 30 days [1 to 180 days]) determined with the clinically validated HPV test was 10% (95% CI 2-18%). With this test, the hrHPV prevalence after transplantation (median time from transplantation: 300 days [120-360 days]) was 14% (95% CI 5-22%) (p = 0.31). Four patients already used immunosuppressive drugs for chronic renal disease at the time of transplantation. Exclusion of these four patients did not change the results. Since there was a variable number of measurements per patient before as well as after transplantation, we used a score system to quantify the degree of HPV positivity in multiple measurements. The mean score for overall HPV positivity before transplantation was 25.5 (mean number of measurements before was 2.26 [range 1-9] in a time period of 1 day to 2 years before transplantation) and the mean score after transplantation was 32.9 (mean number of measurements after was 4.14 [range 1-8] in a time period of >1 month to 2 years after transplantation) with a mean difference of 7.4 (95% CI À3.1 to 17.9; p = 0.163). For hrHPV positivity, the mean score before transplantation with the sensitive HPV test was 17.9 and after transplantation 22.0 with a mean difference of 4.1 (95% CI À4.6 to 12.9; p = 0.349). With the clinically validated HPV test, the mean score was 10 before transplantation and 12.5 after transplantation with a mean difference of 2.5 (95% CI À3.5 to 8.5) (p = 0.41).
In 12/59 patients (20%) the HPV status changed (tested with SPF 10 -LiPA 25 assay) from negative before transplantation to positive after transplantation. We specified the characteristics of these patients in Table 3 . This change in HPV status was not associated with treatment for acute rejection after transplantation. In none of the 12 women who went from HPV negative to HPV positive did we find SIL after transplantation. Notably, lrHPV was detected in two of these women and follow-up time was relatively short for development of (pre)malignant lesions. In 4/59 patients (7%) the HPV status changed from positive before RT to negative after RT. At their first visit, patients received a questionnaire about their relationships and sexual behavior. The answers on this questionnaire are summarized in Table 4 . Every 3 months the patients were asked whether their relationships and/or sexual behavior had changed. Of the 65 patients in whom a transplantation was performed, 11 patients (16.9%) reported a change in sexual behavior after transplantation: 8 became more sexually active while 3 patients reduced their sexual activities. Only one of the eight female RTRs who reported an increase in sexual activities converted from HPV negative to HPV positive after transplantation.
Discussion
This study is the first longitudinal investigation of the cervicovaginal hrHPV prevalence in RTRs before and after RT. Although the study population was limited, we made a number of interesting observations. First, the pretransplant hrHPV prevalence of 10% (measured with the clinically validated Cobas 4800 HPV test) in our cohort was higher than the age-specific hrHPV prevalence in the general population. After transplantation, the hrHPV prevalence was 14%. When an analytically more sensitive HPV test was used, the hrHPV prevalence increased significantly from 19% before to 31% after transplantation without changes in sexual behavior. Apparently there was reactivation of latent HPV infections after RT.
The Cobas 4800 HPV test will be used in the coming Dutch national screening program. In our study all women with clinically relevant cytological abnormalities tested positive with the Cobas 4800 HPV test. However, no significant increase in hrHPV prevalence was found with this test during the first year after transplantation. It is possible that the hrHPV infections due to increased replication after transplantation is likely to result in an increased detection rate with the Cobas 4800 HPV test after a longer followup. On the other hand, using the SPF 10 -LiPA 25 assay, which has a higher analytical sensitivity, we found a significant increase in the prevalence of hrHPV (from 19% to 31%). The prevalence of hrHPV found with this assay after RT is comparable with earlier findings of our study group with the same test in a cohort of 218 female RTRs at different time intervals after transplantation, where a prevalence of 27.1% was observed (17) . The increase of hrHPV prevalence after transplantation was not associated with changes in relationships or sexual behavior. Moreover, the hrHPV prevalence did not change significantly in the control group of patients who did not undergo a RT. Therefore, it is likely that latent HPV infections were reactivated because of immunosuppressive therapy.
Latent viral infections are characterized by a state of reversible nonproductive infection of individual cells (27) . Although the existence of HPV latency is still under Bold results indicates last measurement in period 3-12 months after RT and used in primary analysis. HPV, human papillomavirus; RD, renal disease; FSGS, focal segmental glomerulosclerosis; Tx, transplantation; RT, renal transplantation; Bethesda, Bethesda system 2001 was used for cytological classification; SPF, SPF10-LiPA25 system assay;
Cobas, Cobas 4800 assay; WNL, within normal limits; NA, not available; x, self-sample not available. 1 Measurements used in primary analysis. 2 Only patient who used basiliximab.
American Journal of Transplantation 2017; 17: 1563-1573debate, epidemiological studies convincingly showed that in women who cleared a specific HPV type (tested HPV negative), a recurrent detection of the same genotype can occur without report of (new) sexual contacts (28) (29) (30) (31) . Several studies suggested a role for host immunity in reactivating HPV infections in patients with HIV and in patients who use immunosuppressive drugs (32) (33) (34) (35) . The clinical implications of a reactivation as compared to a recently acquired HPV infection are not clear. However, the increased risk of high-grade neoplasia among HIVinfected and organ transplant recipients suggests that an HPV reactivation carries similar or increased risk of disease development as compared to a de novo infection (36) . The clinical relevance of our findings is supported by several studies that show an increase in cervical-and vulvar cancer rate in RTRs 10 years after the transplantation (14) .
A remarkable finding was the high overall HPV prevalence in patients with ESRD, irrespective of receiving a transplant kidney or not. We had anticipated an overall HPV prevalence of around 10%, according to the overall HPV prevalence in women around 50 years of age (based on HPV testing in 140 000 women with different HPV assays) in the general population (37, 38) . A similar observation with an high overall HPV prevalence was made by Fairley et al (39) , who showed an overall HPV prevalence of 20% in women on maintenance dialysis and of 22% in RTRs compared to 4.5% in women with moderately impaired renal function (serum creatinine 150-390 lmol/L). This may be explained by the fact that cellular immunity is frequently impaired in patients with severe renal failure (40) . Other known risk factors for obtaining an HPV infection, such as smoking (41) (42) (43) (44) and promiscuous sexual behavior (8), were not more prevalent in our patients as compared to the general population. In accordance with the higher prevalence of hrHPV, it has been shown that dialysis patients have an increased risk of cancer, including cervical-and vulvovaginal cancer (45) .
In our study approximately 9% of the patients, who underwent transplantation, had cytological abnormalities at first examination. The incidence of cytological abnormalities in the general population is 7%, but in women aged 50-59 years, which is comparable to the median age of our study population, it is only about 3.5% (46) . At first examination approximately 50% of the patients with cytological abnormalities were on dialysis. This could be an explanation, but the number of patients was too low to assess dialysis as a risk factor. There is no clear explanation for the relatively high percentage of cytological abnormalities in RT patients compared to the group of patients who did not undergo RT.
The results of our study suggest that the start of intensive therapy with immunosuppressive drugs increases the HPV prevalence after transplantation. The higher prevalence during immunosuppression can be explained by several non-mutually exclusive factors, such as a higher susceptibility to become infected with HPV, a higher risk on persistence of the HPV infection, or reactivation of a latent HPV infection. In a small study on HPV subtypes (6, 11, 16, and 18) in female RTRs (16), hrHPV 16 and 18 were found at a higher rate in transplant recipients (55%) compared with their immunocompetent counterparts (15%), placing these patients at increased risk for aggressive anogenital tract (pre)malignant lesions (16) . Notably, at first examination in our study no difference in HPV prevalence was observed between the patients with current or prior use of immunosuppressive drugs compared to those who never did use immunosuppressive drugs. Furthermore, Meeuwis et al (17) showed that the duration of immunosuppressive treatment and the experience of an acute rejection with subsequent intensifying of immunosuppressive therapy were not related to the risk of HPV positivity. The increased hrHPV prevalence in female patients with ESRD raises the question of whether screening for HPV in this patient group would be useful.
Prophylactic vaccines against hrHPV genotypes 16 and 18 are highly effective for the prevention of persistent infections and anogenital cancer. However, recent data showed suboptimal immunogenicity of the quadrivalent HPV vaccine in patients who were treated with immunosuppressive drugs after organ transplantation (47) . Vaccination in patients with renal failure prior to transplantation could be more successful. However, a barrier for implementing HPV vaccination in these women is the wide variety in HPV types found in patients with ESRD. Our study showed 24 different HPV types, which is in accordance with a recent cohort study on HPV infections in female RTRs (17) . Recently, a nonavalent HPV vaccine has been developed to protect against an additional five oncogenic types (31, 33, 45, 52 , and 58 next to 6, 11, 16, and 18) and showed an overall vaccine efficacy of 96.7% in women aged 16-29 years in the general population (48) . Notably, approximately 60% of the HPV-positive patients were infected with genotypes not covered by the nonavalent vaccine. The protective effect of this vaccine in patients with ESRD, especially in sexually active patients, has yet to be demonstrated in prospective studies.
Currently, several European and American guidelines (49-51) recommend intensified cervical cancer screening in female RTRs (14, 16, 52, 53) . hrHPV testing will have an important role in the new cervical screening program in the Netherlands, which will be implemented in 2017. If women test hrHPV negative, no cytological evaluation is necessary and they will receive another invitation in 5 years. In case of hrHPV positivity, there will be cytological evaluation. Cervical cytology will be repeated after 6 months in case of normal cytology and women will be referred to the gynecologist in case of abnormal cytology. If the cytology is normal after 6 months, women return to the regular program (interval of 5 years). A 5-year screening interval in hrHPV-positive RTRs seems relatively long in comparison to existing guidelines. The results of our study emphasize the importance of hrHPV testing in the follow-up of patients who underwent a RT.
However, the precise design of gynecological screening in female RTRs needs to be further discussed.
Our study is the first to prospectively assess HPV prevalence before and after transplantation, which has given us more information on the natural behavior of HPV in RTRs. We used a highly sensitive test to detect HPV DNA in cervicovaginal samples. We did not assess the HPV serology before transplantation because the use of HPV serology to detect naturally acquired HPV infections is not widely accepted. The presence of serum antibodies indicates past infection, but estimates of proportions of women who seroconvert after infection range from 55% to 85%, depending on study design and methods employed. Antibody formation in response to natural infection is a slow process that could extend to over a year (54) (55) (56) . Consequently, the pretransplant serology does not allow reliable interpretation of type-specific acquisition of HPV after transplantation.
A limitation of our study is the relatively short follow-up. Longer follow-up of the hrHPV-positive patients is necessary to determine whether reactivation of latent hrHPV infections leads to dysplasia or cancer.
Conclusion
In this cohort of patients with ESRD, the hrHPV prevalence was higher than the age-specific hrHPV prevalence in the general population. An increase in hrHPV prevalence after transplantation, without any change in sexual behavior, suggests reactivation of latent HPV infections during immunosuppression. This could contribute to the increased risk of HPV-related cervical-and vulvar (pre)malignancies in female RTRs.
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